Leading science, pioneering therapies
CRM Publications

Efficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen.

TitleEfficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen.
Publication TypeJournal Article
Year of Publication2011
AuthorsStacpoole SRL, Bilican B, Webber DJ, Luzhynskaya A, He XL, Compston A, Karadottir R, ffrench-Constant C, Chandran S
JournalNat Protoc
Volume6
Issue8
Pagination1229-40
Date Published2011 Aug
ISSN1750-2799
KeywordsBasic Helix-Loop-Helix Transcription Factors, Cell Culture Techniques, Cell Differentiation, Electrophysiology, Embryonic Stem Cells, Fibroblast Growth Factor 8, Homeodomain Proteins, Humans, Mesencephalon, Morpholines, Motor Neurons, Nerve Tissue Proteins, Neural Stem Cells, Oxygen, Purines, Spinal Nerves, Tretinoin
Abstract

This protocol has been designed to generate neural precursor cells (NPCs) from human embryonic stem cells (hESCs) using a physiological oxygen (O(2)) level of 3% (previously termed hypoxia) and chemically defined conditions. The first stage involves suspension culture of hESC colonies at 3% O(2), where they acquire a neuroepithelial identity over a period of 2 weeks. This timescale is comparable to that observed at 20% O(2), but survival is enhanced. Sequential application of retinoic acid and purmorphamine (PM), from day 14 to day 28, directs differentiation toward spinal motor neurons. Alternatively, addition of fibroblast growth factor-8 and PM generates midbrain dopaminergic neurons. OLIG2 (encoding oligodendrocyte lineage transcription factor 2) induction in motor neuron precursors is twofold greater than that at 20% O(2), whereas EN1 (encoding engrailed homeobox 1) expression is enhanced fivefold. NPCs (at 3% O(2)) can be differentiated into all three neural lineages, and such cultures can be maintained long term in the absence of neurotrophins. The ability to generate defined cell types at 3% O(2) should represent a significant advancement for in vitro disease modeling and potentially for cell-based therapies.

DOI10.1038/nprot.2011.380
Alternate JournalNat Protoc
PubMed ID21799491
PubMed Central IDPMC3433269
Grant List890 / / Multiple Sclerosis Society / United Kingdom
G0300300 / / Medical Research Council / United Kingdom
G0701476 / / Medical Research Council / United Kingdom
G0800487 / / Medical Research Council / United Kingdom
G0800487 / / Medical Research Council / United Kingdom
G0800487(87418) / / Medical Research Council / United Kingdom
G0800784 / / Medical Research Council / United Kingdom
/ / Wellcome Trust / United Kingdom
Publication institute
Other